Evidence map›Paper›PMID 34774126›Full record

ArticleCell chemical biology2022

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

Caitlyn L Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, Debra K Czerwinski, Steven E Artandi, Carolyn R Bertozzi, Ronald Levy, Jennifer R Cochran

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Tangled Tail of Mechanically Interlocked Peptides.Journal of the American Chemical Society · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.Journal of experimental & clinical cancer research : CR · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Caitlyn L MillerDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Idit Sagiv-BarfiDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Patrick NeuhöferDepartment of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Debra K CzerwinskiDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Steven E ArtandiDepartment of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Carolyn R BertozziDepartment of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA.
Ronald LevyDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Jennifer R CochranDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA. Electronic address: jennifer.cochran@stanford.edu.
Stanford University · USHoward Hughes Medical Institute · USStanford Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
REVERSING CELLULAR IMMORTALITY IN CANCERR35CA197563 · NCI · STANFORD UNIVERSITY · PI ARTANDI, STEVEN E · 2015 to 2021
$6.4M
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the HostR35CA197353 · NCI · STANFORD UNIVERSITY · PI LEVY, RONALD · 2016 to 2022
$6.1M
Targeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6M
NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA227942NCI NIH HHS R35 CA197353NCI NIH HHS R35 CA197563
6 · The paper itself

Abstract

Promoting immune activation within the tumor microenvironment (TME) is a promising therapeutic strategy to reverse tumor immunosuppression and elicit anti-tumor immunity. To enable tumor-localized immunotherapy following intravenous administration, we chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant (Toll-like receptor 9 [TLR9] agonist: CpG) to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG. We demonstrate that systemic delivery of PIP-CpG induces tumor regression and enhances therapeutic efficacy compared with untargeted CpG in aggressive murine breast and pancreatic cancer models. Furthermore, PIP-CpG transforms the immune-suppressive TME dominated by myeloid-derived suppressor cells into a lymphocyte-rich TME infiltrated with activated CD8

Indexed as

Adjuvants, ImmunologicNeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorImmunotherapyMiceTumor MicroenvironmentAdjuvants, ImmunologiccancerCpGdrug deliveryimmunotherapyintegrinmyeloid-derived suppressor cellT cellTLR agonistToll-like receptortumor microenvironment

Identifiers

PMID34774126
PMCPMC9134376
OpenAlexW3211961015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.